Portal de Periódicos da CAPES

Discovery of IDO1 Inhibitors: From Bench to Bedside

2017; American Association for Cancer Research; Volume: 77; Issue: 24 Linguagem: Inglês

10.1158/0008-5472.can-17-2285

1538-7445

George C. Prendergast, William P. Malachowski, James B. DuHadaway, Alexander J. Muller,

Bipolar Disorder and Treatment

Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide a bench-to-bedside review on preclinical validation of IDO1 as a cancer therapeutic target and on the discovery and development of a set of mechanistically distinct compounds, indoximod, epacadostat, and navoximod, that were first to be evaluated as IDO inhibitors in clinical trials. As immunometabolic adjuvants to widen therapeutic windows, IDO inhibitors may leverage not only immuno-oncology modalities but also chemotherapy and radiotherapy as standards of care in the oncology clinic. Cancer Res; 77(24); 6795-811. ©2017 AACR.